Merck completes Sigma-Aldrich acquisition

The transaction is worth $17 billion


Merck has made significant progress on integration planning for the new business

Merck has announced the completion of its $17 billion acquisition of Sigma-Aldrich, creating one of the leaders in the $130 billion global industry to help solve the toughest problems in life science.

The completion follows last week's approval from the European Commission, which was the final antitrust condition required to close the Sigma-Aldrich transaction. Following the acquisition, Merck will have around 50,000 employees in 67 countries, working at 72 manufacturing sites worldwide.

"The acquisition of Sigma-Aldrich marks the culmination of almost a decade of transformation, further affirming that Merck is a leading science and technology company," said Mr Karl-Ludwig Kley, CEO and chairman of Merck. "We're now a leading player in the $130 billion global life science industry and together with our two other growth platforms Healthcare and Performance Materials, Merck is set to tackle global challenges that will fundamentally change the world in which we live."

With the acquisition of Sigma-Aldrich, Merck will be able to serve lifescience customers around the world with a highly attractive set of established brands such as SAFC and BioReliance, in addition to Millipore and Milli-Q, as well as an efficient supply chain that can support the delivery of more than 300,000 products. The company will cover every step of the biotech production chain, creating a complete end-to-end workflow with enhanced customer service, a simplified customer interface and a leading distribution platform.

To ensure a smooth integration, Merck has made significant progress on integration planning for the new business, which will be named Merck all across the world, except for the US and Canada, where the business will be named MilliporeSigma. The future organization will tap into the industry-leading talent of both legacy organizations, with a focus on promoting customer centricity, continuous innovation and strengthened capabilities.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email